A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

NCT06049329 · Completed

Last updated 2026-05-28

This clinical trial is testing how a new tablet medication called Amycretin works in Japanese men who have obesity, focusing on its safety.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 36 people

Who can join Ages 18–55 · male only

Timeline Started 2023-09 · est. completion 2023-12

Where 1 site · Japan

What this study is testing ClinicalTrials.gov NCT06049329 ↗

Description as written by the study sponsor.

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.

Treatments tested

NNC0487-0111 Drug

Participants will get one tablet to swallow at the same time of the day.
Placebo (NNC0487-0111) Drug

Participants will get one tablet to swallow at the same time of the day.

Main thing measured	Number of treatment emergent adverse events (TEAE)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	amycretin

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06049329 ↗